These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 34860120)

  • 21. Repository Corticotropin Injection (Acthar
    Wirta D; McLaurin E; Ousler G; Liu J; Kacmaz RO; Grieco J
    Ophthalmol Ther; 2021 Dec; 10(4):1077-1092. PubMed ID: 34669183
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2012 Dec; 12():CD006921. PubMed ID: 23235634
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Wu B; Deshpande G; Gu T; Popelar B; Philbin M; Wan GJ
    J Med Econ; 2017 Nov; 20(11):1170-1177. PubMed ID: 28760047
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effects of 2-year treatment with dimethyl fumarate on cognition and functional impairment in patients with relapsing remitting multiple sclerosis.
    Amato MP; Goretti B; Brescia Morra V; Gallo P; Zaffaroni M; Onofrj M; Cocco E; Borriello G; Zipoli V; Trojano M
    Neurol Sci; 2020 Nov; 41(11):3185-3193. PubMed ID: 32358701
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mitoxantrone in relapsing-remitting and rapidly progressive multiple sclerosis: Ten-year clinical outcomes post-treatment with mitoxantrone.
    Foo EC; Russell M; Lily O; Ford HL
    Mult Scler Relat Disord; 2020 Sep; 44():102330. PubMed ID: 32599468
    [TBL] [Abstract][Full Text] [Related]  

  • 26. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naïve patients, and previously treated patients.
    Ziemssen T; Calabrese P; Penner IK; Apfel R
    J Neurol; 2016 Apr; 263(4):784-91. PubMed ID: 26914926
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Retrospective Medical Record Review to Describe Use of Repository Corticotropin Injection Among Patients with Uveitis in the United States.
    Nelson WW; Lima AF; Kranyak J; Opong-Owusu B; Ciepielewska G; Gallagher JR; Heap K; Carroll S
    J Ocul Pharmacol Ther; 2019 Apr; 35(3):182-188. PubMed ID: 30676837
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development and evaluation of an interactive web-based decision-making programme on relapse management for people with multiple sclerosis (POWER@MS2)-study protocol for a randomised controlled trial.
    Rahn AC; Wenzel L; Icks A; Stahmann A; Scheiderbauer J; Grentzenberg K; Vomhof M; Montalbo J; Friede T; Heesen C; Köpke S
    Trials; 2021 Feb; 22(1):139. PubMed ID: 33583424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Repository corticotropin injection in patients with advanced symptomatic sarcoidosis: retrospective analysis of medical records.
    Chopra I; Qin Y; Kranyak J; Gallagher JR; Heap K; Carroll S; Wan GJ
    Ther Adv Respir Dis; 2019; 13():1753466619888127. PubMed ID: 31722624
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Relapse prevalence, symptoms, and health care engagement: patient insights from the Multiple Sclerosis in America 2017 survey.
    Nazareth TA; Rava AR; Polyakov JL; Banfe EN; Waltrip Ii RW; Zerkowski KB; Herbert LB
    Mult Scler Relat Disord; 2018 Nov; 26():219-234. PubMed ID: 30368080
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Repository corticotropin injection in multiple sclerosis: an update.
    Kutz CF; Dix AL
    Neurodegener Dis Manag; 2018 Aug; 8(4):217-225. PubMed ID: 29869572
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repository corticotropin for Chronic Pulmonary Sarcoidosis.
    Baughman RP; Sweiss N; Keijsers R; Birring SS; Shipley R; Saketkoo LA; Lower EE
    Lung; 2017 Jun; 195(3):313-322. PubMed ID: 28353116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab for relapsing-remitting multiple sclerosis.
    He D; Guo R; Zhang F; Zhang C; Dong S; Zhou H
    Cochrane Database Syst Rev; 2013 Dec; (12):CD009130. PubMed ID: 24310855
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CLICK-MS and MASTER-2 Phase IV trial design: cladribine tablets in suboptimally controlled relapsing multiple sclerosis.
    Miravalle AA; Katz J; Robertson D; Hayward B; Harlow DE; Lebson LA; Sloane JA; Bass AD; Fox EJ
    Neurodegener Dis Manag; 2021 Apr; 11(2):99-111. PubMed ID: 33517769
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.
    Burton JM; O'Connor PW; Hohol M; Beyene J
    Cochrane Database Syst Rev; 2009 Jul; (3):CD006921. PubMed ID: 19588409
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Repository corticotropin injection versus corticosteroids for protection against renal damage in a focal segmental glomerulosclerosis rodent model.
    Hayes K; Warner E; Bollinger C; Wright D; Fitch RM
    BMC Nephrol; 2020 Jun; 21(1):226. PubMed ID: 32539845
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of ketogenic diets in relapsing multiple sclerosis: safety, tolerability and potential clinical benefits.
    Brenton JN; Lehner-Gulotta D; Woolbright E; Banwell B; Bergqvist AGC; Chen S; Coleman R; Conaway M; Goldman MD
    J Neurol Neurosurg Psychiatry; 2022 Jun; 93(6):637-644. PubMed ID: 35418509
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recovery of cognitive function after relapse in multiple sclerosis.
    Benedict RH; Pol J; Yasin F; Hojnacki D; Kolb C; Eckert S; Tacca B; Drake A; Wojcik C; Morrow SA; Jakimovski D; Fuchs TA; Dwyer MG; Zivadinov R; Weinstock-Guttman B
    Mult Scler; 2021 Jan; 27(1):71-78. PubMed ID: 31971066
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.